Sun Pharma profit falls on one-time loss

Sun Pharma reported second-quarter net profit of ₹1,989 cr, down 36% year on year, according to Moneycontrol. Revenue stood at ₹16,199 cr, while the headline attributed the earnings pressure to a one-time loss. The result marks a separate pharmaceutical-sector development from the earlier Cipla earnings report, which covered a 35% fall in profit.

The one-time charge is central to interpreting the decline because it distinguishes an exceptional hit from recurring operating pressure. The revenue figure will therefore be important alongside management commentary on product demand, pricing, regional performance and margins. A lower profit despite the reported revenue base leaves investors focused on how much of the weakness was accounting-related and how much came from underlying business operations 💊.

OI Charts data for 29 Oct 2026 showed the stock at ₹1,761, up 0.20% on the day, with volume of 1,107,854. It had gained 1.0% over five sessions but remained down 4.9% over 20 sessions. The stock’s 52-week range was ₹1,584 to ₹2,047, with the high recorded on 31 Jul 2026 and the low on 29 Jan 2026.

Derivatives positioning showed futures open interest down 0.7% on the session, classified as short covering, while futures traded at a 0.51% premium to the underlying. The options put-call ratio was 0.88, with maximum pain at ₹1,760 for the 23 Nov 2026 expiry. The largest call open interest was at ₹1,800 and the largest put open interest at ₹1,700, placing those levels around the near-term options positioning

The next focus is the detailed results presentation and management explanation of the one-time loss, followed by margin and business-segment commentary. Trading volume and whether the stock holds the ₹1,700–₹1,800 options range will show how participants are assessing the difference between exceptional and recurring earnings pressure.

Source: Moneycontrol.com, 30 Oct 2026

Not investment advice. For informational purposes only.